MedTrace Logo

Neuroprolotherapy With Physical Therapy for Treatment of Patellar Chondromalacia

NCT03515720 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2023-10-03

No results posted yet for this study

Summary

Patellar chondromalacia is the degeneration of articular cartilage located on the posterior face of the patella and may suggest the onset of an osteoarthrosis. It predominates in sedentary people who overload the joint, as well as people with insufficiency in the extensor muscles of the knee. It is often seen between 30 and 40 years. Conservative management is the main treatment option and surgical intervention is considered as a last option in a small number of patients. A new treatment option is neuroprolotherapy where the approach is directed at the subcutaneous nerves as the source of pathology, which can lead to neurogenic inflammation and pain.

Conditions

  • Chondromalacia Patellae

Interventions

PROCEDURE

Prolotherapy

It consists of injecting 5% dextrose in sterile aqueous solution without the use of lidocaine in a subcutaneous nerve to inhibit neurogenic inflammation and the release of substance P and CGRP, decreasing neurogenic inflammation.

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Principal Investigators

  • Cleotilde Fuentes Orozco, PhD, MD · High Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute

  • Roberto Mares País, MD · High Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute

  • Sandra Angélica García Triana, MD · Unit of Physical Medicine and Rehabilitation, High Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute

  • María Fernanda Toro Sashida, MD · Unit of Physical Medicine and Rehabilitation, High Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute

  • Francisco José Barbosa Camacho, MD · High Specialty Medical Unit, National Western Medical Center, Mexican Social Security Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
SEQUENTIAL

Eligibility

Min Age
25 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-01
Primary Completion
2019-09-20
Completion
2020-03-01

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03515720 on ClinicalTrials.gov